Thomi, R; Yerly, Daniel; Yawalkar, Nikhil; Simon, Dagmar; Schlapbach, Christoph; Hunger, Robert (2017). Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa. British journal of dermatology, 177(5), pp. 1358-1366. Wiley-Blackwell 10.1111/bjd.15458
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
Thomi_et_al-2017-British_Journal_of_Dermatology.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (897kB) |
|
|
Text
IL-32 revision.pdf - Accepted Version Available under License Publisher holds Copyright. Download (237kB) | Preview |
BACKGROUND
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Its immunopathogenic mechanisms are still poorly understood. Previous studies demonstrated that the proinflammatory cytokine interleukin (IL)-32 is implicated in the pathogenesis of other inflammatory diseases.
OBJECTIVES
To investigate the tissue expression and systemic levels of IL-32, as well as its cellular sources, in patients with HS in comparison with healthy donors and patients with two other inflammatory skin diseases: psoriasis and atopic dermatitis (AD).
METHODS
Tissue samples were obtained from healthy skin and lesional HS, psoriatic and AD skin to analyse the expression of IL-32 by immunohistochemistry and semiquantitative real-time polymerase chain reaction. The cellular source of the cytokine was determined by double immunofluorescence staining. Serum from the four donor groups was used to measure systemic levels of IL-32 by enzyme-linked immunosorbent assay.
RESULTS
IL-32 was upregulated in patients with HS in both lesional skin and serum when compared with healthy donors and patients with AD or psoriasis. In HS, IL-32 was found to be expressed by natural killer cells, T cells, macrophages and dendritic cells in highly infiltrated areas of the dermis. High IL32 mRNA levels in lesional HS skin coincided with high amounts of T cells and macrophages. Additionally, IL32 mRNA levels in lesional HS skin correlate positively with interferon-γ and IL-17A and negatively with IL-13.
CONCLUSIONS
Our findings suggest that IL-32 is overexpressed in HS. Targeting IL-32 may therefore represent a new therapeutic option for the treatment of this recalcitrant disease.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology and Immunology 04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology |
UniBE Contributor: |
Yerly, Daniel, Yawalkar, Nikhil, Simon, Dagmar, Schlapbach, Christoph, Hunger, Robert |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0007-0963 |
Publisher: |
Wiley-Blackwell |
Language: |
English |
Submitter: |
Andrea Studer-Gauch |
Date Deposited: |
19 Feb 2018 16:28 |
Last Modified: |
05 Dec 2022 15:10 |
Publisher DOI: |
10.1111/bjd.15458 |
PubMed ID: |
28301691 |
BORIS DOI: |
10.7892/boris.110244 |
URI: |
https://boris.unibe.ch/id/eprint/110244 |
Actions (login required)
 |
Edit item |